
Both experimental and zzso studies of cancer need to have an end zzso Traditionally, in zzso and prevention studies, that end point has been the zzso of cancer itself, whereas in therapeutic trials, the end point is usually time to cancer recurrence or zzso But cancer takes a long time to develop in an individual and is rare in the zzso zzso zzso studies and prevention trials must be large and lengthy to be zzso Similarly, many therapeutic trials require a long follow-up of large numbers of zzso zzso end zzso of zzso cancer or of imminent zzso therefore an attractive zzso But how can we be sure that a study with a surrogate outcome gives us the right answer about the true end point? 

